Get the Stockscreener App
0.39
2.50%
-0.01
After Hours:
.41
0.02
+5.13%
Ensysce Biosciences Inc stock is traded at $0.39, with a volume of 105.81K.
It is down -2.50% in the last 24 hours and down -30.25% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$0.40
Open:
$0.4049
24h Volume:
105.81K
Relative Volume:
0.02
Market Cap:
$3.62M
Revenue:
$5.07M
Net Income/Loss:
$-10.18M
P/E Ratio:
-0.0925
EPS:
-4.2178
Net Cash Flow:
$-7.93M
1W Performance:
+7.94%
1M Performance:
-30.25%
6M Performance:
-81.16%
1Y Performance:
-82.03%
1-Day Range:
$0.39
$0.4266
1-Week Range:
$0.3403
$0.4354
52-Week Range:
$0.3144
$2.75
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.39 | 3.71M | 5.07M | -10.18M | -7.93M | -4.2178 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
ENSC Ensysce Biosciences reports narrower Q4 2025 loss than estimates, shares climb after earnings release.Barrier to Entry - Newser
ENSC Should I Buy - Intellectia AI
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences (ENSC) Sector Trends | Q4 2025: EPS Beats ForecastsCommunity Chart Signals - UBND thành phố Hải Phòng
Ensysce Biosciences : Corporate Overview - marketscreener.com
Ensysce receives IRB approval for final opioid overdose study phase By Investing.com - Investing.com India
Ensysce Biosciences Secures IRB Approval for Final Phase of Clinical Study - National Today
Ensysce receives IRB approval for final opioid overdose study phase - Investing.com
Opioid with built-in overdose safeguard enters final study stage - Stock Titan
[EFFECT] Ensysce Biosciences, Inc. SEC Filing - Stock Titan
Price Action: Will Ensysce Biosciences Inc benefit from geopolitical trendsTrade Volume Summary & Weekly High Potential Alerts - baoquankhu1.vn
Bull Run: Is Ensysce Biosciences Inc subject to activist investor interest2026 Dividend Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
What is the volatility of Ensysce Biosciences (ENSC) Stock | Price at $0.48, Up 0.21%Growth Investing - Newser
Ensysce Biosciences (NASDAQ: ENSC) registers 20.3M resale shares - Stock Titan
Ensysce Biosciences Secures $2 Million Second Tranche Financing to Advance Abuse-Resistant Pain Therapies - Minichart
Ensysce Biosciences Secures $2 Million Private Financing - TipRanks
Ensysce Biosciences (NASDAQ: ENSC) closes $2M preferred and warrant deal - Stock Titan
Ensysce Raises $2 Million in Private Placement of Series B Preferred and Warrants - TradingView
Can Ensysce Biosciences (ENSC) Stock Beat Estimates | Price at $0.55, Down 4.96%Real Trader Network - Newser
Ensysce Biosciences closes $2M convertible preferred financing By Investing.com - Investing.com South Africa
Ensysce Biosciences Secures Second Financing to Advance Pain Programs - National Today
Ensysce Biosciences closes $2M convertible preferred financing - Investing.com
Pain drug developer pulls another $2M for overdose-resistant treatments - Stock Titan
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs - The Globe and Mail
Aug Swings: Does Ensysce Biosciences Inc meet Warren Buffetts criteria2026 Patterns & Reliable Intraday Trade Alerts - baoquankhu1.vn
Stop Loss: Whats the RSI of PETWW stock2026 Sector Review & Real-Time Volume Triggers - baoquankhu1.vn
Is Ensysce Biosciences (ENSC) Stock in a Selling Zone | Price at $0.58, Down 5.12%Price Target - Newser
Ensysce Biosciences, Inc. Announces Director Resignation in April 2026 Form 8-K Filing - Minichart
Ensysce Biosciences director Curtis Rosebraugh resigns from board By Investing.com - Investing.com India
Ensysce Biosciences director Curtis Rosebraugh resigns from board - Investing.com
Ensysce Biosciences Announces Board Member Curtis Rosebraugh Resignation - TipRanks
Board member Curtis Rosebraugh exits Ensysce Biosciences (NASDAQ: ENSC) - Stock Titan
ENSC Stock Analysis: Ensysce Biosciences Inc biotech gains 11.52 percent to 0.61 dollars - UBND thành phố Hải Phòng
ENSC SEC FilingsEnsysce Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ENSC Gains Ground as Investors Pile In - Newser
Ensysce Biosciences, Inc. — Business Overview, Risk Factors, Regulatory Approvals, and Intellectual Property Challenges 64 - Minichart
8-K: Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - bitget.com
Smart Money: Will Ensysce Biosciences Inc benefit from geopolitical trendsWeekly Market Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Ensysce Biosciences (NASDAQ: ENSC) outlines abuse-resistant opioid pipeline - Stock Titan
ENSC: Net loss widened to $10.2 million in 2025; ongoing operations depend on new capital raises - TradingView — Track All Markets
Ensysce Biosciences Reports Q4 and Full Year 2025 Results - National Today
Ensysce (NASDAQ: ENSC) advances PF614 programs as 2025 net loss hits $10.2M - Stock Titan
Ensysce Biosciences Q4 net loss narrows to $2.8 mln - TradingView
Ensysce pushes abuse-deterrent opioid into late-stage testing - Stock Titan
Ensysce Biosciences (NASDAQ: ENSC) director quits after opposing retention deals - stocktitan.net
Revenue Check: Does Ensysce Biosciences Inc meet Warren Buffetts criteria2026 Highlights & Low Risk High Reward Ideas - baoquankhu1.vn
ENSC Stock Price, Quote & Chart | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Weekly Trades: Is Ensysce Biosciences Inc a turnaround story2026 Snapshot & Fast Exit and Entry Trade Guides - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):